Currently, there are 49.05M common shares owned by the public and among those 46.48M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The company’s stock has a 5-day price change of -3.89% and -22.73% over the past three months. MNOV shares are trading -9.33% year to date (YTD), with the 12-month market performance down to -41.13% lower. It has a 12-month low price of $1.30 and touched a high of $2.66 over the same period. MNOV has an average intraday trading volume of 126.81K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.86%, -9.60%, and -32.04% respectively.
Institutional ownership of Medicinova Inc (NASDAQ: MNOV) shares accounts for 18.87% of the company’s 49.05M shares outstanding.
It has a market capitalization of $66.71M and a beta (3y monthly) value of 0.74. The earnings-per-share (ttm) stands at -$0.17. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.99% over the week and 4.67% over the month.
Analysts forecast that Medicinova Inc (MNOV) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for 2024. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$0.06 a year ago. Earnings per share for the fiscal year are expected to decrease by -88.24%, and -9.37% over the next financial year. EPS should grow at an annualized rate of 20.00% over the next five years, compared to 13.30% over the past 5-year period.
Looking at the support for the MNOV, a number of firms have released research notes about the stock. Maxim Group stated their Buy rating for the stock in a research note on March 10, 2021, with the firm’s price target at $15.
